EVEROLIMUS

everolimus 10 mg tablet, 30

EVEROLIMUS (10135K)

everolimus 10 mg tablet, 30
10135K
Body System:
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET)
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 30 # of repeats: 5 DPMQ: $1,738.71 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Afinitor